SCHEMBL35211024

SCHEMBL35211024

COC(=O)c1cn(C)c2cc(-c3nc(Cl)ncc3F)cc(F)c12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 9/20 0.37
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CDK4 P11802 2/20 0.33
CCND3 P30281 2/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
KDR P35968 1/20 0.33
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CCND1 P24385 1/20 0.32
CDK6 Q00534 1/20 0.32
KCNQ3 O43525 2/20 0.32
KCNQ2 O43526 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35210956 0.87 CDK4 (0.35) CDK4CCND3CDK1CCNB1CCNA2
SCHEMBL35210674 0.84 NR4A2 (0.46) NR4A2KDM4EALDH1A1RAB9ASMN1; SMN2
SCHEMBL35210687 0.80 CDK4 (0.38) CDK4CCND3CCND1CDK6
SCHEMBL22097954 0.77 NPC1 (0.41) KDM4ERAB9ASMN1; SMN2MAPTSCN5A
SCHEMBL30633791 0.75 CDK4 (0.38) KDM4EALDH1A1CDK4CCND3CDK1
SCHEMBL35210577 0.74 KCNH2 (0.38) CDK4CCND3CDK1CCNB1CCNA2
SCHEMBL24619257 0.74 KDM4E (0.35) KDM4EALDH1A1RAB9ASMN1; SMN2CDK4
SCHEMBL29727189 0.74 KDM4E (0.35) KDM4EALDH1A1RAB9ASMN1; SMN2CDK4
SCHEMBL35210579 0.73 NR4A2 (0.48) NR4A2KDM4EALDH1A1RAB9ASMN1; SMN2
SCHEMBL24619168 0.73 PSMD14 (0.40) NR4A2KDM4EALDH1A1NFKB1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125391-A1 PYRIMIDINE INDOLES AS CDK4 INHIBITORS INCYTE CORP (US) 2026-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125391-A1 PYRIMIDINE INDOLES AS CDK4 INHIBITORS CDK4, CCNA1, CCNO NR4A2 179/4885KDM4E 1827/4885ALDH1A1 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.